Intellectual property is one of the most valued assets of life science companies. As such, founders can be strategic while planning to help minimize the risk of ever reaching the point of entering into an IP dispute. By identifying and managing potential IP disputes from the onset, companies can focus efforts on other growth matters, such as running a thriving business.
Lori Doyle
ldoyle@wsgr.com
Maya Skubatch was a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati and a former member of the firm’s board of directors. Maya focused on strategic patent counseling for both private and public life science companies. She worked closely with licensing, litigation, corporate, and regulatory counsel to provide integrated IP strategies and often assists clients with intellectual property matters pertaining to financings, M&A, and partnership deals. Maya also worked with investors on IP diligence matters.
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
Kristina Hanson is a partner in the San Francisco office of Wilson Sonsini Goodrich & Rosati. Her practice primarily focuses on intellectual property litigation, with an emphasis on pharmaceutical patent matters arising under the Hatch-Waxman Act. She has represented clients in a variety of pharmaceutical matters, from pre-trial strategy counseling through appeals.
Natalie Morgan focuses her practice primarily on patent litigation, and she has been trial counsel in jury, bench, International Trade Commission, and arbitration trials in patent cases. Her cases have covered diverse technologies, including life sciences, biotechnology, pharmaceuticals in Hatch-Waxman patent litigation, and medical devices, as well as software, graphical user interfaces, electronic trading, cellular and wireless telecommunications, and mechanical products in varied fields.
Deborah Smith leads Wilson Sonsini’s Patents and Innovations practice in Southern California. She advises high-growth biotechnology and pharmaceutical companies and their investors on IP strategy across the full product lifecycle—from platform development through drug approval, commercialization, and exit—spanning modalities including small molecules, ADCs, degraders, molecular glues, peptides, nucleic acid therapeutics, biologics, and protein conjugates. Her work spans patent strategy, portfolio development, IP due diligence, and IP matters tied to regulatory approval, as well as transactional matters including buy-side and sell-side M&A, licensing, financings, IPOs, and reverse mergers.